A Comparison of Active Surveillance Programs Including a Spontaneous Reporting Model for Phamacovigilance of Adverse Drug Events in a Hospital
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Spontaneous reporting systems have several weak points, such as low reporting rates and insufficient clinical information. Active surveillance programs, such as ward rounds and a clinical data repository (CDR), may supplement the weak points of such systems. We developed active surveillance programs and compared them with existing spontaneous reporting. Methods: We collected adverse drug event (ADE) cases, which comprised 1,055 cases of spontaneous reporting, 309 reported by ward rounds, and 229 found using a CDR. The clinical features and causative drugs were evaluated. Results: Active surveillance programs detected additional serious ADEs compared to those of spontaneous reporting programs. The ADEs identified by CDR (22.9%) were more likely to be classified as “serious” than those reported spontaneously (5.2%) or identified during ward rounds (10.3%). Causative drugs also differed. Opioids, antibiotics, and contrast media were the most common drugs causing ADEs in the spontaneous reporting system, whereas the active surveillance programs identified antibiotics as the most common causative drug. Clinical features also differed. ADEs with gastrointestinal manifestations were reported most frequently by spontaneous reporting programs. ADEs reported from active surveillance more reliably identified events associated with changes in laboratory values, such as hepatobiliary toxicity, hematologic manifestations, and nephrologic manifestations, compared with spontaneous reporting programs. Conclusions: Our findings suggest that active surveillance programs can supplement spontaneous reporting systems in hospitals. ADEs related to laboratory abnormalities were monitored more closely by active surveillance programs and may be useful for identification of serious ADEs.
Abstract
Background/Aims: Spontaneous reporting systems have several weak points, such as low reporting rates and insufficient clinical information. Active surveillance programs, such as ward rounds and a clinical data repository (CDR), may supplement the weak points of such systems. We developed active surveillance programs and compared them with existing spontaneous reporting. Methods: We collected adverse drug event (ADE) cases, which comprised 1,055 cases of spontaneous reporting, 309 reported by ward rounds, and 229 found using a CDR. The clinical features and causative drugs were evaluated. Results: Active surveillance programs detected additional serious ADEs compared to those of spontaneous reporting programs. The ADEs identified by CDR (22.9%) were more likely to be classified as “serious” than those reported spontaneously (5.2%) or identified during ward rounds (10.3%). Causative drugs also differed. Opioids, antibiotics, and contrast media were the most common drugs causing ADEs in the spontaneous reporting system, whereas the active surveillance programs identified antibiotics as the most common causative drug. Clinical features also differed. ADEs with gastrointestinal manifestations were reported most frequently by spontaneous reporting programs. ADEs reported from active surveillance more reliably identified events associated with changes in laboratory values, such as hepatobiliary toxicity, hematologic manifestations, and nephrologic manifestations, compared with spontaneous reporting programs. Conclusions: Our findings suggest that active surveillance programs can supplement spontaneous reporting systems in hospitals. ADEs related to laboratory abnormalities were monitored more closely by active surveillance programs and may be useful for identification of serious ADEs.
참고문헌 (33)
- Forster AJ, "Pharmacist surveillance of adverse drug events", Am J Health Syst Pharm, 61, pp.1466~1472 (2004)
- Leape LL, "The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II", N Engl J Med, 324, pp.377~384 (1991)
- Thomas EJ, "Incidence and types of adverse events and negligent care in Utah and Colorado", Med Care, 38, pp.261~271 (2000)
- Classen DC, "Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality", JAMA, 277, pp.301~306 (1997)
- Senst BL, "Practical approach to determining costs and frequency of adverse drug events in a health care network", Am J Health Syst Pharm, 58, pp.1126~1132 (2001)
- Bates DW, "Incidence of adverse drug events and potential adverse drug events: implications for prevention: ADE Prevention Study Group", JAMA, 274, pp.29~34 (1995)
- Nebeker JR, "High rates of adverse drug events in a highly computerized hospital", Arch Intern Med, 165, pp.1111~1116 (2005)
- Bates DW, "The costs of adverse drug events in hospitalized patients: Adverse Drug Events Prevention Study Group", JAMA, 277, pp.307~311 (1997)
- Leape LL, "Systems analysis of adverse drug events: ADE Prevention Study Group", JAMA, 274, pp.35~43 (1995)
- Raschke RA, "A computer alert system to prevent injury from adverse drug events: development and evaluation in a community teaching hospital", JAMA, 280, pp.1317~1320 (1998)
- Weaver J, "Informatic tools and approaches in postmarketing pharmacovigilance used by FDA", AAPS J, 10, pp.35~41 (2008)
- Zancan A, "A new model of pharmacovigilance? A pilot study", Biomed Pharmacother, 63, pp.451~455 (2009)
- Bates DW, "Incidence and preventability of adverse drug events in hospitalized adults", J Gen Intern Med, 8, pp.289~294 (1993)
- Keith MR, "Multidisciplinary program for detecting and evaluating adverse drug reactions", Am J Hosp Pharm, 46, pp.1809~1812 (1989)
- Jha AK, "Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report", J Am Med Inform Assoc, 5, pp.305~314 (1998)
- Gandhi TK, "Identifying drug safety issues: from research to practice", Int J Qual Health Care, 12, pp.69~76 (2000)
- Hwang SH, "Evaluation of a computer-based adverse-drug-event monitor", Am J Health Syst Pharm, 65, pp.2265~2272 (2008)
- Faich GA, "National adverse drug reaction reporting: 1984-1989", Arch Intern Med, 151, pp.1645~1647 (1991)
- Berry LL, "Sensitivity and specificity of three methods of detecting adverse drug reactions", Am J Hosp Pharm, 45, pp.1534~1539 (1988)
- Rogers AS, "Physician knowledge, attitudes, and behavior related to reporting adverse drug events", Arch Intern Med, 148, pp.1596~1600 (1988)
- Schiff GD, "Using a computerized discharge summary data base check box for adverse drug reaction monitoring", QRB Qual Rev Bull, 16, pp.149~155 (1990)
- Cullen DJ, "The incident reporting system does not detect adverse drug events: a problem for quality improvement", Jt Comm J Qual Improv, 21, pp.541~548 (1995)
- The Uppsala Monitoring Centre, "The WHO-ART Adverse Reaction Terminology", The Uppsala Monitoring Centre, ~ (1992)
- Edwards IR, "Adverse drug reactions: definitions, diagnosis, and management", Lancet, 356, pp.1255~1259 (2000)
- Vallano A, "Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital", Br J Clin Pharmacol, 60, pp.653~658 (2005)
- Miwa LJ, "Adverse drug reaction program using pharmacist and nurse monitors", Hosp Formul, 21, pp.1140~1146 (1986)
- Marcondes RA, "Dental care of the cardiac patient", Ars Curandi Odontol, 2, pp.3~8 (1976)
- Hunziker T, "Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey", Allergy, 52, pp.388~393 (1997)
- 최정희, "단일 3차 의료기관에서 약물 이상 반응의 빈도", 대한내과학회지, 67(3), pp.290~296 (2004), 대한내과학회
- Classen DC, "Computerized surveillance of adverse drug events in hospital patients", JAMA, 266, pp.2847~2851 (1991)
- Kunac DL, "Incidence, preventability, and impact of Adverse Drug Events (ADEs) and potential ADEs in hospitalized children in New Zealand: a prospective observational cohort study", Paediatr Drugs, 11, pp.153~160 (2009)
- Kaushal R, "Medication errors and adverse drug events in pediatric inpatients", JAMA, 285, pp.2114~2120 (2001)
- Holdsworth MT, "Incidence and impact of adverse drug events in pediatric inpatients", Arch Pediatr Adolesc Med, 157, pp.60~65 (2003)